IgA nephropathy clinical trials

Explore recruiting iga nephropathy clinical trials.

Recruiting iga nephropathy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

IgA nephropathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN)

Germany, Czechia, Belgium, Greece, Poland, Denmark +7 more

Phase II and Phase III (Integrated) EU CTIS Study details

Therapeutic effect of Hydroxychloroquine on IgA Nephropathy course QUIgAN Study

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients

Italy, Netherlands, Belgium, Hungary, Slovenia, Spain +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open-label, uncontrolled, multicenter study to assess the effect of zigakibart treatment on histologic, circulating, and excreted markers of kidney disease and dysfunction in adult patients with IgA nephropathy

Czechia, Germany, Spain, Italy, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects with IgA Nephropathy on Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) (The ASSIST study)

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Felzartamab in Adults with IgA Nephropathy (299IG301 / PREVAIL)

Greece, Portugal, Spain, Croatia, Czechia, Belgium +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

IgA nephropathy trials by city

IgA nephropathy in Toronto IgA nephropathy in Vancouver IgA nephropathy in Montreal IgA nephropathy in Calgary IgA nephropathy in Edmonton IgA nephropathy in Ottawa IgA nephropathy in Winnipeg IgA nephropathy in Quebec City IgA nephropathy in Hamilton IgA nephropathy in Kitchener IgA nephropathy in London IgA nephropathy in Halifax IgA nephropathy in New York IgA nephropathy in Los Angeles IgA nephropathy in Chicago IgA nephropathy in Houston

Other conditions

Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease Polycystic kidney disease Migraine Alzheimer's disease Parkinson's disease Multiple sclerosis Epilepsy ALS Huntington's disease Peripheral neuropathy Restless legs syndrome Essential tremor Dementia